house · trading 2015-11-02 → 2024-11-21
*Notional-weighted price return on disclosed buys, marked to the latest close — open positions, per-share (share counts aren't disclosed, so this is price performance, not realized $ P&L).
| Date | Ticker | Type | Amount | Est. price | Latest close | Return |
|---|---|---|---|---|---|---|
| 2020-12-17 | NET | BUY | $1K–$15K | $81.82 | $237.24 2026-06-26 | +189.9% |
| 2020-10-23 | SP | BUY | $1K–$15K | — | — | — |
| 2020-10-06 | SP | BUY | $1K–$15K | — | — | — |
| 2019-11-11 | NTAP | BUY | $1K–$15K | $59.87 | $152.45 2026-06-26 | +154.6% |
| 2019-09-16 | NTAP | BUY | $1K–$15K | $56.84 | $152.45 2026-06-26 | +168.2% |
| 2019-07-15 | SP | BUY | $1K–$15K | — | — | — |
| 2019-05-08 | NTAP | BUY | $1K–$15K | $68.92 | $152.45 2026-06-26 | +121.2% |
| 2019-04-15 | NTAP | BUY | $1K–$15K | $76.16 | $152.45 2026-06-26 | +100.2% |
| 2018-09-28 | NTAP | SELL | $1K–$15K | $85.89 | $152.45 2026-06-26 | +25.7% rt |
| 2018-09-28 | NTAP | BUY | $1K–$15K | $85.89 | $152.45 2026-06-26 | +77.5% |
| 2018-09-05 | NXTAPP | BUY | $1K–$15K | — | — | — |
| 2018-05-01 | NTAP | SELL | $1K–$15K | $67.85 | $152.45 2026-06-26 | +8.0% rt |
| 2018-04-23 | NTAP | BUY | $1K–$15K | $68.35 | $152.45 2026-06-26 | +123.0% |
| 2018-03-22 | NTAP | SELL | $1K–$15K | $62.16 | $152.45 2026-06-26 | +6.9% rt |
| 2018-03-19 | NTAP | BUY | $1K–$15K | $62.84 | $152.45 2026-06-26 | +142.6% |
| 2018-02-06 | NTAP | BUY | $1K–$15K | $58.14 | $152.45 2026-06-26 | +162.2% |
| 2017-12-05 | NTAP | SELL | $1K–$15K | $56.14 | $152.45 2026-06-26 | +28.7% rt |
| 2017-12-01 | NTAP | SELL | $1K–$15K | $56.41 | $152.45 2026-06-26 | +52.0% rt |
| 2017-11-21 | NTAP | SELL | $1K–$15K | $55.08 | $152.45 2026-06-26 | +69.5% rt |
| 2017-11-07 | NTAP | SELL | $1K–$15K | $44.65 | $152.45 2026-06-26 | +37.7% rt |
| 2017-10-31 | NTAP | SELL | $1K–$15K | $44.42 | $152.45 2026-06-26 | +30.9% rt |
| 2017-10-27 | NTAP | SELL | $1K–$15K | $44.01 | $152.45 2026-06-26 | +29.9% rt |
| 2017-10-16 | NTAP | SELL | $1K–$15K | $43.72 | $152.45 2026-06-26 | +26.0% rt |
| 2017-10-14 | NTAP | BUY | $1K–$15K | $43.63 | $152.45 2026-06-26 | +249.4% |
| 2016-11-21 | NTAP | BUY | $1K–$15K | $37.12 | $152.45 2026-06-26 | +310.7% |
| 2016-11-08 | NTAP | BUY | $1K–$15K | $32.49 | $152.45 2026-06-26 | +369.2% |
| 2016-11-02 | NTAP | BUY | $1K–$15K | $32.42 | $152.45 2026-06-26 | +370.2% |
| 2016-10-31 | NTAP | BUY | $1K–$15K | $33.94 | $152.45 2026-06-26 | +349.2% |
| 2016-10-13 | NTAP | BUY | $1K–$15K | $33.87 | $152.45 2026-06-26 | +350.1% |
| 2016-08-22 | NTAP | SELL | $1K–$15K | $34.71 | $152.45 2026-06-26 | +37.1% rt |
| 2016-08-19 | NTAP | BUY | $1K–$15K | $34.71 | $152.45 2026-06-26 | +339.2% |
| 2016-06-20 | NTAP | BUY | $1K–$15K | $25.31 | $152.45 2026-06-26 | +502.3% |
| 2015-11-17 | GSK | SELL | $1K–$15K | $40.63 | $52.50 2026-06-26 | -29.2% exit |
| 2015-11-12 | GSK | SELL | $1K–$15K | $40.05 | $52.50 2026-06-26 | -7.1% rt |
| 2015-11-07 | NAT | SELL | $1K–$15K | $15.02 | $5.85 2026-06-26 | -2.1% rt |
| 2015-11-07 | GSK | SELL | $1K–$15K | $41.92 | $52.50 2026-06-26 | -8.8% rt |
| 2015-11-02 | NAT | BUY | $1K–$15K | $15.34 | $5.85 2026-06-26 | -61.9% |
| 2015-11-02 | GSK | BUY | $1K–$15K | $43.11 | $52.50 2026-06-26 | +21.8% |
| NTAP | SELL | $1K–$15K | — | — | — exit | |
| NTAP | BUY | $1K–$15K | — | — | — | |
| NTAP | BUY | $1K–$15K | — | — | — | |
| META | BUY | $1K–$15K | — | — | — |
Return: buys are marked to the latest close (open); sells tagged rt are realized round-trips vs a prior disclosed buy; exit = timing (how the stock moved after the sale, seller's perspective).
| Member | Shared tickers |
|---|---|
| Hon. Rohit Khanna | 5 · GSK, META, NTAP, SP, SPY |
| Hon. Mike Kelly | 4 · GSK, META, SP, SPY |
| JOHN BOOZMAN | 4 · GSK, META, NTAP, SPY |
| Hon. Rob Bresnahan | 3 · META, NET, SPY |
| Hon. Josh Gottheimer | 3 · META, NET, SPY |
| THOMAS R CARPER | 3 · GSK, NTAP, SPY |
| Hon. Kurt Schrader | 2 · GSK, SPY |
| Hon. Virginia Foxx | 2 · GSK, NAT |
| Hon. Kenny Marchant | 2 · GSK, SPY |
| Hon. James B. Renacci | 2 · GSK, SPY |
| Hon. K. Michael Conaway | 2 · GSK, SPY |
| Hon. Charles J. "Chuck" Fleischmann | 2 · GSK, SPY |